Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
The medications address the biological drivers of obesity (hormonal signaling, appetite regulation) but do not permanently rewire these systems
doi: 10.1210/en.2004-1427 207 YuePJinHAillaudMDengACAzumaJAsagamiTet al
Published in JAMA Network Open in 2024, the research dives into whether bariatric surgery or GLP-1 receptor agonist drugs offer a better shot at extending life for those battling both conditions
Soc 62 (1), 6772
GLP-1s are used primarily to treat people with Type 2 diabetes and, in some cases, obesity
The Precision Peptide Genetic Test maps pathway-level variants such as FTO, and MC4R that apply across GLP-1 biology, so it offers upstream context relevant to the entire category
